MedTrace Logo

Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)

NCT07509749 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-04-03

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for the severe acute GVHD (graft-versus-host disease )

Conditions

  • GVHD, Acute
  • Stem Cell Transplant Complications

Interventions

DRUG

Ruxolitinib and Methylprednisolone

Participants began oral administration of ruxolitinib at 5 mg QD; Methylprednisolone (1mg/kg)

DRUG

Methylprednisolone

Methylprednisolone 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.

Sponsors & Collaborators

  • Daihong Liu

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-30
Primary Completion
2027-12-30
Completion
2027-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07509749 on ClinicalTrials.gov